文献速递甲状腺疾病

表达促甲状腺激素受体A亚基的腺病毒诱导Graves眼病小鼠模型

A Promising Mouse Model of Graves' Orbitopathy Induced by Adenovirus Expressing Thyrotropin Receptor A Subunit.
PubMed 文献 · Thyroid · 2021-01-05

研究通过9次肌肉注射表达人促甲状腺激素受体A亚基的腺病毒(Ad-TSHRA)免疫雌性BALB/C小鼠,成功建立Graves眼病(GO)模型,成模频率为70%。模型再现了眶后纤维化、脂肪生成、突眼等人类GO特征,并揭示Th1细胞比例升高、Th2和Treg细胞比例降低以及T细胞免疫的关键作用,首次提示从Graves甲亢到GO的潜在时间窗口。

要点

  • 9次Ad-TSHRA注射可诱导70%小鼠出现GO样眶部改变。
  • 眶部病变先于甲状腺增生之后出现,提示从甲亢到GO的时间窗口。
  • GO小鼠脾脏Th1细胞比例升高,Th2和Treg细胞比例降低。

核心结论

  • 9次注射Ad-TSHRA成功建立GO小鼠模型,成模频率为70%,并揭示T细胞免疫的重要性。
  • 模型首次呈现从Graves甲亢到GO的潜在时间窗口,可用于研究发病机制和新疗法。

研究设计与样本

  • 雌性BALB/C小鼠肌肉注射表达人TSH受体A亚基的腺病毒(Ad-TSHRA)9次以诱导GO。
  • 在预定时间点进行眶后组织和甲状腺组织学检查、血清自身抗体和总甲状腺素水平检测。
  • 采用流式细胞术分析CD4+ T细胞亚群,并对脾细胞进行RNA测序以探索机制。

主要发现

  • 9次注射后,10只Ad-TSHRA攻击小鼠中7只出现GO相关眶部改变。
  • 7只小鼠表现为眶后纤维化,4只显示脂肪生成,部分小鼠观察到突眼、结膜充血和眶内淋巴细胞浸润。
  • 眶病最早在7次注射后检测到,并紧随4次注射后观察到的甲状腺增生性改变。
  • 流式细胞术显示GO小鼠脾脏Th1细胞比例增加,Th2细胞和调节性T(Treg)细胞比例降低,眶部免疫组化染色证实该CD4+ T细胞亚群变化。
  • RNA-Seq显示GO小鼠中T细胞受体信号、增殖、黏附、炎症和细胞毒性相关基因上调;4次注射后无眶病的甲亢小鼠中这些GO特异性基因呈上调趋势。

临床怎么用

  • 该模型可用于研究GO发病机制及评估新治疗方法。
  • T细胞免疫特别是Th1/Th2/Treg平衡可能作为GO干预的潜在靶点。
  • 从甲亢到GO的时间窗口提示需在甲亢阶段关注眶部病变的早期监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Graves' orbitopathy (GO) is the most common and serious manifestation of Graves' disease (GD). It is characterized by orbital inflammation and tissue remodeling. Although several GO models have been reported, most lack a full assessment or mechanistic evaluation. Here, we established a promising mouse model mimicking many aspects of human GO with a frequency of 70% and characterized the key role of T cells in the progression of GO. Methods: An adenovirus expressing the human thyrotropin (TSH) receptor A subunit (Ad-TSHRA) was injected in the muscles of female BALB/C mice nine times to induce GO. At predetermined time points, histological examinations of retrobulbar tissues and thyroid glands were performed to dynamically monitor changes; serum autoantibodies and total thyroxine levels were examined to evaluate thyroid function. Flow cytometry of CD4+ T cell subgroups and RNA sequencing (RNA-Seq) of splenocytes were also performed to explore the underlying mechanism. Results: After nine injections, 7 of 10 mice challenged with Ad-TSHRA developed the orbital changes associated with GO. Seven mice manifested retrobulbar fibrosis, and four mice showed adipogenesis. Exophthalmia, conjunctival redness, and orbital lymphocyte infiltration were also observed in a subset of mice. The orbitopathy was first detected after seven injections and followed the hyperplastic change observed in thyroids after four injections. Flow cytometry revealed increased proportions of Th1 cells and decreased proportions of Th2 cells and regulatory T (Treg) cells in the splenocytes of GO mice. This change in CD4+ T cell subgroups was confirmed by orbital immunohistochemical staining. Genes involved in T cell receptor signaling, proliferation, adhesion, inflammation, and cytotoxicity were upregulated in GO mice according to the RNA-Seq; a trend of upregulation of these GO-specific genes was observed in mice with hyperthyroidism without orbitopathy after four injections. Conclusions: A GO mouse model was successfully established by administering nine injections of Ad-TSHRA. The model was achieved with a frequency of 70% and revealed the importance of T cell immunity. A potential time window from Graves' hyperthyroidism to GO was presented for the first time. Therefore, this model could be used to study the pathogenesis and novel treatments for GO.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Zhang M, Ding X, Wu LP, et al. A Promising Mouse Model of Graves' Orbitopathy Induced by Adenovirus Expressing Thyrotropin Receptor A Subunit. Thyroid. 2021. PMID: 33076782. doi:10.1089/thy.2020.0088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。